ArticleMolecular therapy. Oncology2025
Perturbed CD81 in lung-cancer-derived extracellular vesicles modifies its function in cancer pathophysiology.
Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Exosome-mediated organotropism in breast cancer metastasis: bridging the gap between molecular mechanisms and clinical application.Clinical & experimental metastasis · 2026Review
- A Putative Hsa-miR-582-5p-CD81 Relationship Identified by Integrative Transcriptomic Analysis in Osteosarcoma.International journal of molecular sciences · 2026Article
- Genomic innovations in cancer prevention, diagnosis, prognosis and precision therapeutics.Frontiers in genetics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Lung cancer (LC) remains a leading cause of cancer-related fatalities, necessitating an urgent need for potent treatment strategies. This study investigates the role of extracellular vesicle (EV) cargo: CD81 in lung cancer progression and its potential as a therapeutic target. CD81 is a tetraspanin protein that has garnered considerable interest in regulating angiogenesis in various cancer types, including LC. Our study unveiled the presence of elevated levels of CD81 in EVs derived from LC cell lines and patient-derived tumoroids compared to disease-free counterparts, suggesting a potential role in cancer pathogenesis. EVs derived from CD81-silenced LC cells (EV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.